Business
PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference
BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide
About this update from Pepgen Inc.
[{"type":"text","content":"BOSTON, March 13, 2023 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that it will present at the Muscular Dystrophy Association (MDA) Annual Clinical and Scientific Conference, taking place on March 19-22, 2023 in Dallas, Texas. PepGen intends to issue a press release concurrent with the conclusion of the Company’s presentations, and plans to post the poster presentation and data presentations on the Events and Presentations page in the Investor Relations section of the company’s website. Podium Presentations: Title: Positive Results from a First-in-Human Study Support Continued Development of PGN EDO51 for the Treatment of Duchenne Muscular Dystrophy (DMD)Abstract Number: #95Session Topic: Clinical Trials Date & Time: Wednesday, March 22, 2023 at 3:00pm ETPresenter: Michelle Mellion, M.D., Senior Vice President, Head of Clinical Development Title: PGN-EDODM1 Nonclinical Data Demonstrate Potential for Meaningful Impact in Myotonic Dystrophy Type 1 (DM1): Support for Phase 1 Clinical Trial DesignAbstract Number: #306Session Topic: Translational ResearchDate & Time: Wednesday, March 22, 2023 at 10:15am ETPresenter: Jane Larkindale, Ph.D., Vice President, Clinical Science Poster Presentation: Title: Nonclinical Data Demonstrate the Potential of the Enhanced Delivery Oligonucleotide (EDO) PGN-EDO51 for the Treatment of Duchenne Muscular DystrophyAbstract Number: #242Session Topic: Preclinical ResearchDate & Time: Poster presentation available throughout the conference from March 19-22, 2023Presenter: Ashling Holland, Ph.D., Director of Preclinical Development About PepGen PepGen Inc. is a clinical-stage biotechnology company advancing the next-generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases. PepGen’s Enhanced Delivery Oligonucleotide, or EDO, platform is founded on over a decade of research and development and leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Using these EDO peptides, we are generating a pipeline of oligonucleotide therapeutic candidates that target the root ca...